CTOs on the Move


 
Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.opiant.com
  • 233 Wilshire Boulevard Suite 280
    Santa Monica, CA USA 90401
  • Phone: 424.252.4756

Executives

Name Title Contact Details

Similar Companies

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

U.S. Urology Partners

U.S. Urology Partners is a physician-led management services organization that provides business support services to our network of urology practices .

VioQuest Pharmaceuticals

VioQuest Pharmaceuticals is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cornell Communications

Emergency call systems from wireless nurse call systems to wireless emergency response pendants and door monitoring systems